Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10 Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt , Ph.D., Chief Executive Officer; Jason Tardio , M.B.A., Chief Operating Officer and President; Andreas Muehler , M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof , Ph.D., Chief Scientific Officer, will be joined by two of the MS industry's renowned experts to discuss the MS landscape as well as Immunic's orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients. Date: Tuesday, September 10, 2024 Time: 10:30 am to 12:30 pm ET , followed by a networking lunch Location: One Five One, 151 West 42nd S
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]Yahoo! Finance
- 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyPR Newswire
- Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Immunic to Present at the November 21st Virtual Investor Summit Microcap EventAccesswire
IMUX
Earnings
- 11/7/24 - Miss
IMUX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMUX's page on the SEC website